<< Revenir à la page d'accueil
13th november 2012
Maison de la Chimie, Paris
Implementing personalized medicines for metastatic breast cancer patients
Fabrice ANDRE
Inserm Université Paris Sud - Institut Gustave-Roussy, Villejuif
⤢
Implementing personalized medicines for metastatic breast cancer patients
Genomic variations lead to heterogeneity of treatment response
Molecular Medicine Program Deliverable for each patient: treatment according to genomic profiling
Personalized and stratified medicine in metastatic breast cancer
Outline
Illustration: SAFIR01 Trial Design
SAFIR01 Accrual
Results and Interpretation: September 2012
MOSCATO I trial
Outline
Does this molecular screening speed-up drug development ?
Clinical Response
Outline
Biomarker studies SAFIR01 trial: Molecular characterisation of the metastatic disease
Next Steps
SAFIR program: moving to SAFIR02
SAFIR02: study design
Conclusion and Perspectives
Clinical trials and Samples collections (Breast cancers)
|«
«
▶||
»
»|
0:00:00